30 closest matches · ranked by relevance
HIV Enteropathy · Diarrhea With HIV
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants
HIV Associated Diarrhea
Primary: Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose…
HIV Disease
Primary: Change in Breath Test — 28; 14 ppm
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
HIV Infections · Immunological Abnormality
Primary: CD4+ Level — 162.3; 50.5; 143.3; 69.9 cell/μL — p=0.02
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
HIV · Hepatitis C, Chronic · HCV Coinfection
Primary: Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. — 5.8; 5.84; 5.84; 6.9 relative expression levels
HIV Related Insulin Resistance · Protease Inhibitor Related Insulin Resistance · Endoplasmic Reticulum Stress
Primary: Glucose Uptake — 0; 8 change in glucose infusion rate (ml/hr)
HIV
Primary: Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study — 0.0067; 0.0035 mcg/mL — p=0.51
HIV-associated Enteropathy
Primary: Frequency of Daily Unformed Bowel Movements — -2.46; -2.16; -2.20 abnormal or unformed stools
HIV Infection · Rotavirus Infection
Primary: Percentage of Participants Developing New Grade >=3 Adverse Events — 1.6; 4.7; 13.5; 12.8 Percentage of participants — p=0.62
HIV · Tuberculosis
Primary: Number of Serious Adverse Events (SAEs) — 12; 7 Events
HIV
Primary: Number of Bowel Movements Per Day — 5.8; 2 bowel movements/day — p=0.008
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Human Immunodeficiency Virus
Primary: Adverse Effects — 1 Participants
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
HIV (Human Immunodeficiency Virus) · AIDS (Acquired Immunodeficiency Syndrome)
Primary: Symptom Burden Score — 1.08; 1.06; 0.83; 0.71 score on a scale — p=0.02
Human Immunodeficiency Virus Infection
Primary: Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV — 80; 478; 213 cells / mm^2…
HIV-associated Co-morbidities
Primary: 25(OH)D Levels — 13; 20 Participants
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
HIV Infection
Primary: Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups — 0.19; 0.09 percent change…
HIV · Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
HIV
Primary: Changes in Gut Microbial Translocation (iFABP) — 145.76; 125.36; 151.5; 111.73 pg/mL
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05
Antibiotic-associated Diarrhea
Primary: Change From Baseline Levels of Fecal Short-chain Fatty Acid (With a Particular Focus on Acetate) — 23.55; -13.9; -19.5; 7.25 micromolar
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio